NEW YORK, Jan. 12, 2016 /PRNewswire-USNewswire/ -- PsychoGenics Inc. and the Alzheimer's Drug Discovery Foundation (ADDF) announce a new partnership to bring PsychoGenics' validated Alzheimer's animal models and experimental services to ADDF grantees working on preclinical Alzheimer's drug discovery programs. Through the partnership, PsychoGenics will establish risk-sharing agreements with ADDF-funded biotechnology companies to make its services available under extremely favorable financial terms, thus increasing the value of the ADDF's grants.
Dr. Howard Fillit, Executive Director and Chief Science Officer of the ADDF, says, "We are delighted to collaborate with PsychoGenics to make its expertise and services available to our Alzheimer's research community. This beneficial partnership will allow our critical funding to go further. Together, we will accelerate preclinical drug discovery programs in our portfolio and move closer to our goal of developing new treatments for Alzheimer's disease."
PsychoGenics' services that will be available to ADDF-funded researchers include behavioral pharmacology, including its unique high content behavioral testing using its Cube® technologies; state-of-the-art electrophysiology; translational EEG; microdialysis; a wide range of biochemical methods; quantitative histological methods; and several widely used, licensed APP and tauopathy animal models.
Dr. Emer Leahy, President and CEO of PsychoGenics, states, "We are extremely pleased to align with the ADDF, an organization that enables leading scientists to pursue cutting-edge research projects that might otherwise go unexplored. Programs that apply for ADDF funding go through a very rigorous review process and those that are funded hold great promise. Through our risk-sharing arrangement, we can help some of the most promising programs go further and fast track the development of effective therapies for the significant unmet medical needs associated with Alzheimer's disease, dementia and cognitive aging."
PsychoGenics is a leader in in vivo phenotypic drug discovery. The company applies its proprietary technology platforms in partnership with pharmaceutical and biotechnology companies to discover the next generation of drugs for CNS disorders. PsychoGenics' capabilities also include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis. In addition to Alzheimer's disease models, the company also offers a variety of in-licensed transgenic mouse models that support research in areas such as Huntington's disease, Autism spectrum disorders, psychosis/schizophrenia, Parkinson's disease, Spinal Muscular Atrophy (SMA), muscular dystrophy and other muscle disorders. Visit www.PsychoGenics.com.
About the Alzheimer's Drug Discovery Foundation
Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation (ADDF) is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, the ADDF has awarded $80 million to fund nearly 500 Alzheimer's drug discovery programs and clinical trials in 18 countries. To learn more, please visit: http://www.alzdiscovery.org/.
SOURCE Alzheimer's Drug Discovery Foundation